BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25216674)

  • 1. MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.
    Mishra S; Lin CL; Huang TH; Bouamar H; Sun LZ
    Mol Cancer; 2014 Sep; 13():212. PubMed ID: 25216674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of p57Kip2 induces prostate cancer in the mouse.
    Jin RJ; Lho Y; Wang Y; Ao M; Revelo MP; Hayward SW; Wills ML; Logan SK; Zhang P; Matusik RJ
    Cancer Res; 2008 May; 68(10):3601-8. PubMed ID: 18483241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57
    Li X; Ruan X; Zhang P; Yu Y; Gao M; Yuan S; Zhao Z; Yang J; Zhao L
    Oncogene; 2018 May; 37(21):2773-2792. PubMed ID: 29511350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
    Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
    Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Beckwith-Wiedemann-Associated
    Stampone E; Bencivenga D; Barone C; Di Finizio M; Della Ragione F; Borriello A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.
    Zhao R; Yang HY; Shin J; Phan L; Fang L; Che TF; Su CH; Yeung SC; Lee MH
    Cell Cycle; 2013 Mar; 12(6):935-43. PubMed ID: 23421998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p57(Kip2) knock-in mouse reveals CDK-independent contribution in the development of Beckwith-Wiedemann syndrome.
    Duquesnes N; Callot C; Jeannot P; Daburon V; Nakayama KI; Manenti S; Davy A; Besson A
    J Pathol; 2016 Jul; 239(3):250-61. PubMed ID: 27015986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long non-coding RNA Kcnq1ot1 controls maternal p57 expression in muscle cells by promoting H3K27me3 accumulation to an intragenic MyoD-binding region.
    Andresini O; Rossi MN; Matteini F; Petrai S; Santini T; Maione R
    Epigenetics Chromatin; 2019 Jan; 12(1):8. PubMed ID: 30651140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome.
    Grandjean V; Smith J; Schofield PN; Ferguson-Smith AC
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5279-84. PubMed ID: 10779549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p57KIP2: "Kip"ing the cell under control.
    Pateras IS; Apostolopoulou K; Niforou K; Kotsinas A; Gorgoulis VG
    Mol Cancer Res; 2009 Dec; 7(12):1902-19. PubMed ID: 19934273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
    Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors.
    Tury A; Mairet-Coello G; DiCicco-Bloom E
    Cereb Cortex; 2011 Aug; 21(8):1840-56. PubMed ID: 21245411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p57(Kip2) and cancer: time for a critical appraisal.
    Borriello A; Caldarelli I; Bencivenga D; Criscuolo M; Cucciolla V; Tramontano A; Oliva A; Perrotta S; Della Ragione F
    Mol Cancer Res; 2011 Oct; 9(10):1269-84. PubMed ID: 21816904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.
    Yan Y; Frisén J; Lee MH; Massagué J; Barbacid M
    Genes Dev; 1997 Apr; 11(8):973-83. PubMed ID: 9136926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation.
    Kim M; Nakamoto T; Nishimori S; Tanaka K; Chiba T
    EMBO Rep; 2008 Sep; 9(9):878-84. PubMed ID: 18660753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
    Chow SE; Wang JS; Lin MR; Lee CL
    J Cell Biochem; 2011 Nov; 112(11):3459-68. PubMed ID: 21769918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
    Vlachos P; Joseph B
    Oncogene; 2009 Nov; 28(47):4175-88. PubMed ID: 19734939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer.
    Kim YK; Yu J; Han TS; Park SY; Namkoong B; Kim DH; Hur K; Yoo MW; Lee HJ; Yang HK; Kim VN
    Nucleic Acids Res; 2009 Apr; 37(5):1672-81. PubMed ID: 19153141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients.
    Biaoxue R; Xiguang C; Hua L; Hui M; Shuanying Y; Wei Z; Wenli S; Jie D
    Int J Biol Markers; 2011; 26(1):9-21. PubMed ID: 21360479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor.
    Cucciolla V; Borriello A; Criscuolo M; Sinisi AA; Bencivenga D; Tramontano A; Scudieri AC; Oliva A; Zappia V; Della Ragione F
    Carcinogenesis; 2008 Mar; 29(3):560-7. PubMed ID: 18204075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.